When Patents Conflict with the Right to Life: Should Intellectual Property Yield to Humanity's Right to Treatment?

The greatness of laws is not measured by their ability to protect rights under normal circumstances; rather, their true value is tested when rights collide with one another.

One of the most complex forms of this collision in the modern era is that which arises between a private right, represented by the legal protection of pharmaceutical patents, and a public right, embodied in human life and health.

If a pharmaceutical company succeeds, after years of research and investment, in discovering a cure for a fatal disease, and the law grants it a patent that allows it to monopolize its exploitation for twenty years, and then it becomes apparent that millions of patients are unable to obtain the medicine due to its high price, does the monopoly remain legitimate? Or does the law, which was created to protect innovation, become a reason for depriving humans of their right to life?

This question is no longer a philosophical hypothesis; rather, it has become one of the most pressing legal and ethical dilemmas in the international system.

The patent system was established to achieve a noble goal, which is to encourage innovation. An inventor does not spend years of their life and billions of dollars in scientific research unless they are assured of the existence of legal protection that guarantees they can recover their investments and achieve a legitimate return.

Hence, a patent is not a free privilege, but rather the compensation that society grants to the innovator in exchange for disclosing their invention to the public, allowing for the transfer of knowledge after the protection period expires.

However, this legal philosophy sometimes collides with a harsher reality.

In the field of pharmaceutical industries, the subject of the monopoly is not a luxury commodity or a recreational product, but rather a medicine upon which human life may depend.

Here, the dispute shifts from an economic disagreement to an existential question: Is it permissible for the right to life to become hostage to the ability to pay?

The right to health and the right to life are among the fundamental rights enshrined in international conventions, foremost among which are the Universal Declaration of Human Rights and the International Covenant on Economic, Social and Cultural Rights, both of which obligate states to strive to provide the highest attainable standard of health for all individuals.

In contrast, the TRIPS Agreement recognized the rights of patent holders, but it did not make these rights absolute. Instead, under specific circumstances, it permitted recourse to exceptional mechanisms, including compulsory licensing, which allows the state to license the production or importation of a medicine without the consent of the patent owner, while granting them fair compensation, whenever necessity dictates, particularly in cases of health emergencies and public interest.

The existence of this mechanism reveals a profoundly important legal fact: that the international community itself did not consider intellectual property rights to be rights that transcend all other rights, but rather subjected them to the principle of balance between private interest and public interest.

This trend was clearly manifested in the Doha Declaration on the TRIPS Agreement and Public Health, which affirmed that the interpretation of the provisions of the TRIPS Agreement must be carried out in a manner that supports the right of states to protect public health and ensures access to essential medicines for all.

Here, the question arises: Is compulsory licensing alone sufficient to achieve justice?

The answer, in my view, is: No.

Compulsory licensing remains an exceptional remedy, while global health crises reveal the need to reconsider the philosophy of the relationship between intellectual property and medicine.

Legal protection should not turn into absolute economic immunity, nor should the protection of public health become a pretext for confiscating the rights of innovators.

The real challenge does not lie in the triumph of one right at the expense of the other, but rather in building a system that achieves a balance between them.

It is possible to achieve this balance by expanding the use of compulsory licensing in cases of epidemics, encouraging technology transfer to developing countries, and supporting international funds to compensate innovating companies when their medicines are made available to low-income countries, as well as promoting collaborative scientific research models in which public and private institutions share the risks and rewards of innovation.

Innovation needs protection, but life needs priority.

Hence, the real question is not: Should pharmaceutical patents be abolished?

Rather, it is: How do we maintain the incentive to innovate without this incentive becoming a barrier that stands between the patient and their right to treatment?

The law, in its essence, is not a tool to protect funds, nor is it a means to entrench monopoly; rather, it is a system for achieving justice.

And if the general rule is that intellectual property rights must be respected, then the exception imposed by humanitarian necessity is not a detraction from these rights, but rather an embodiment of their loftiest purpose.

Intellectual property was created to serve humanity, and humanity was not created to serve intellectual property.

When a judge, a legislator, or the international community stands at a crossroads between protecting a patent and protecting a human life, the question that must remain present is not: How much is the medicine worth in the market? But rather: How much is life worth in the scales of justice?